Perioperative Amiodarone to Prevent Atrial fibrillation after Septal Myectomy in obstrUctive hypeRtroPHic cardiomyopathy.
Sign Up to like & getrecommendations! Published in 2021 at "ESC heart failure"
DOI: 10.1002/ehf2.13662
Abstract: AIMS Amiodarone reduces the incidence of atrial fibrillation (AF) following coronary artery bypass surgery; however, the benefit of perioperative amiodarone in patients undergoing septal myectomy (SM) for obstructive hypertrophic cardiomyopathy (oHCM) has not been studied.… read more here.
Keywords: atrial fibrillation; perioperative amiodarone; amiodarone; septal myectomy ... See more keywords
Treatment patterns, outcomes and healthcare resource utilization of obstructive hypertrophic cardiomyopathy in England
Sign Up to like & getrecommendations! Published in 2025 at "ESC Heart Failure"
DOI: 10.1002/ehf2.15213
Abstract: Describe patient characteristics, treatment patterns, clinical outcomes, healthcare resource utilization (HCRU) and medical costs associated with patients who were diagnosed with obstructive hypertrophic cardiomyopathy (HCM) in clinical practice in England. read more here.
Keywords: outcomes healthcare; obstructive hypertrophic; resource utilization; hypertrophic cardiomyopathy ... See more keywords
Effect of beta‐blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.2737
Abstract: In the EXPLORER‐HCM trial, mavacamten improved exercise capacity and symptoms in patients with obstructive hypertrophic cardiomyopathy (oHCM). Mavacamten effects on the primary endpoint, a composite of peak oxygen consumption (VO2) and New York Heart Association… read more here.
Keywords: beta blocker; hypertrophic cardiomyopathy; obstructive hypertrophic; beta ... See more keywords
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial
Sign Up to like & getrecommendations! Published in 2020 at "The Lancet"
DOI: 10.1016/s0140-6736(20)31792-x
Abstract: BACKGROUND Cardiac muscle hypercontractility is a key pathophysiological abnormality in hypertrophic cardiomyopathy, and a major determinant of dynamic left ventricular outflow tract (LVOT) obstruction. Available pharmacological options for hypertrophic cardiomyopathy are inadequate or poorly tolerated… read more here.
Keywords: placebo; treatment; obstructive hypertrophic; nyha class ... See more keywords
Early outcomes of septal myectomy for obstructive hypertrophic cardiomyopathy in children with Noonan syndrome.
Sign Up to like & getrecommendations! Published in 2021 at "Seminars in thoracic and cardiovascular surgery"
DOI: 10.1053/j.semtcvs.2021.07.027
Abstract: Noonan syndrome (NS) is a genetic syndrome causing obstructive hypertrophic cardiomyopathy (HCM) in infants. Studies of cardiac surgery in pediatric HCM patients with NS (NS-HCM) are lacking. We aim to characterize the early disease course… read more here.
Keywords: noonan syndrome; hcm patients; hypertrophic cardiomyopathy; hcm ... See more keywords
Frequency and clinicoeconomic impact of delays to definitive diagnosis of obstructive hypertrophic cardiomyopathy in the United States.
Sign Up to like & getrecommendations! Published in 2023 at "Journal of medical economics"
DOI: 10.1080/13696998.2023.2208966
Abstract: AIMS The diagnostic history in the years leading up to the definitive diagnosis of patients with obstructive hypertrophic cardiomyopathy (HCM) has not been studied. METHODS Patients with a delay in the definitive diagnosis of obstructive… read more here.
Keywords: hypertrophic cardiomyopathy; obstructive hcm; obstructive hypertrophic; diagnosis ... See more keywords
Aficamten in the treatment of obstructive hypertrophic cardiomyopathy.
Sign Up to like & getrecommendations! Published in 2025 at "Future cardiology"
DOI: 10.1080/14796678.2025.2521183
Abstract: Aficamten is a novel cardiac myosin inhibitor that has completed a Phase III trial for the treatment of obstructive hypertrophic cardiomyopathy (HCM). Aficamten was developed to optimize pharmacokinetic properties and clinical tolerability relative to its… read more here.
Keywords: treatment obstructive; hypertrophic cardiomyopathy; obstructive hypertrophic; aficamten treatment ... See more keywords
Infective endocarditis in obstructive hypertrophic cardiomyopathy: a case series and literature review
Sign Up to like & getrecommendations! Published in 2020 at "Chinese Medical Journal"
DOI: 10.1097/cm9.0000000000001265
Abstract: To the Editor: Infective endocarditis (IE) is a rare complication of hypertrophic cardiomyopathy (HCM) that may lead to fatal outcomes if the infection is not effectively controlled. We report three cases of hypertrophic obstructive cardiomyopathy… read more here.
Keywords: obstructive hypertrophic; hypertrophic cardiomyopathy; infective endocarditis; endocarditis obstructive ... See more keywords
Sex differences in clinical outcomes for obstructive hypertrophic cardiomyopathy in the USA: a retrospective observational study of administrative claims data
Sign Up to like & getrecommendations! Published in 2022 at "BMJ Open"
DOI: 10.1136/bmjopen-2021-058151
Abstract: Objectives To evaluate sex differences in demographic and clinical characteristics, treatments and outcomes for patients with diagnosed obstructive hypertrophic cardiomyopathy (oHCM) in the USA. Setting Retrospective observational study of administrative claims data from MarketScan Commercial… read more here.
Keywords: hypertrophic cardiomyopathy; obstructive hypertrophic; retrospective observational; fibrillation ... See more keywords
Abstract 17141: Mavacamten Improves Left Ventricular Relaxation and Compliance in Obstructive Hypertrophic Cardiomyopathy Through Direct Myosin Modulation
Sign Up to like & getrecommendations! Published in 2018 at "Circulation"
DOI: 10.1161/circ.138.suppl_1.17141
Abstract: Introduction: Obstructive hypertrophic cardiomyopathy (oHCM) consists of a constellation of LV hypercontractility, LV outflow tract obstruction (LVOTO), and impaired relaxation, often resulting in dyspnea and reduced exercise capacity. In healthy dogs, the novel myosin modulator… read more here.
Keywords: relaxation; myosin; hypertrophic cardiomyopathy; compliance ... See more keywords
Abstract 13590: Demographic and Clinical Characteristics of Patients With Obstructive Hypertrophic Cardiomyopathy in a Large, Nationwide Us Cohort
Sign Up to like & getrecommendations! Published in 2020 at "Circulation"
DOI: 10.1161/circ.142.suppl_3.13590
Abstract: Background: Obstructive hypertrophic cardiomyopathy (oHCM) has mostly been studied in patients treated in advanced comprehensive Centers of Excellence (COE). Understanding the true prevalence of patients with oHCM in the general US population may improve the… read more here.
Keywords: obstructive hypertrophic; clinical characteristics; characteristics patients; cohort ... See more keywords